速溶片的市场规模、份额和成长分析（按药物类别、适应症、分销管道和地区）：产业预测（2025-2032）

2023年全球速溶片市场规模为56亿美元，从2024年的61亿美元成长到2032年的120.6亿美元，预计预测期内（2025-2032年）复合年增长率为8.9。

由于对无需水或咀嚼即可溶解的固态口服剂型的需求不断增加，速溶锭剂市场正在不断增长。此创新解决方案适合活跃人士、老年人和吞嚥困难人士，确保在各种环境下都能获得药物。口腔溶解药物传递系统的最新进展增强了药物治疗的快速介入、提高的生物有效性和增强的稳定性等能力。使用者友善的製造流程和稳定的剂量使其成为治疗需要快速起效的病症的理想选择，例如晕动病、过敏发作和急性咳嗽。因此，速溶片剂正成为寻求有效且方便的药物治疗的不同人群的重要选择。

目录

介绍

• 分析目的
• 市场范围
• 定义

分析方法

• 资讯采购
• 次要/主要资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 市场概况及展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及前景

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特分析

主要市场考虑因素

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场魅力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术分析
• 监管分析
• 专利分析
• 案例研究

全球速溶片市场规模/复合年增长率：按药物类别划分（2025-2032）

• 市场概况
• 抗精神病药物
• 抗癫痫药
• 中枢神经系统兴奋剂
• 抗焦虑药
• 抗帕金森氏症药物
• 抗高血压药
• 非类固醇消炎剂
• 抗过敏药
• 质子帮浦抑制剂
• 其他的

全球速溶片市场规模与复合年增长率：依适应症分类（2025-2032）

• 市场概况
• 中枢神经系统疾病
• 消化系统疾病
• 中枢神经系统 (CVS) 疾病
• 过敏
• 其他的

全球速溶片市场规模/复合年增长率：依分销管道划分（2025-2032）

• 市场概况
• 医院药房
• 零售药房
• 药局
• 网路药房

全球速溶片市场规模/复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争格局

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要企业采取的策略
• 近期市场趋势
• 主要企业市场占有率（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• 梯瓦製药工业股份有限公司（以色列）
• 诺华公司（瑞士）
• 阿斯特捷利康（英国）
• 迈兰 NV（美国）
• 辉瑞公司（美国）
• 强生服务公司（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• 默克公司（美国）
• 博士健康（加拿大）
• 葛兰素史克公司（英国）
• 太阳製药工业有限公司（印度）
• 拜耳公司（德国）
• 礼来公司（美国）
• 雷迪博士实验室有限公司（印度）
• 武田药品工业株式会社（日本）
• 吉祥製药有限公司（日本）
• Zydus Lifesciences 有限公司（印度）
• Torrent 製药有限公司（印度）
• 西普拉有限公司（印度）
• Aurobindo Pharma Ltd.（印度）

结论和建议

Global Fast Melt Tablets Market size was valued at USD 5.6 billion in 2023 and is poised to grow from USD 6.1 billion in 2024 to USD 12.06 billion by 2032, growing at a CAGR of 8.9% during the forecast period (2025-2032).

The fast-melting tablet market is experiencing growth due to the increasing demand for solid oral dosage forms that dissolve without the need for water or chewing. This innovative solution caters to active individuals, the elderly, and those with swallowing difficulties, ensuring drug accessibility in various scenarios. Recent advancements in oral-dissolving drug delivery systems have enhanced their capabilities, offering rapid intervention for drug therapy, improved bioavailability, and enhanced stability. Their user-friendly manufacturing process and consistent dosing make them ideal for handling conditions such as motion sickness, allergic attacks, or acute coughing, where a quick onset of action is essential. As a result, fast-dissolving tablets are becoming an essential option for diverse demographics seeking effective and convenient medication solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Fast Melt Tablets market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Fast Melt Tablets Market Segmental Analysis

Global Fast Melt Tablets Market is segmented by Drug Class, Indication, Distribution channel and region. Based on Drug Class, the market is segmented into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensive, NSAIDS, Anti-Allergy Drugs, Proton Pump Inhibitors and Others. Based on Indication, the market is segmented into CNS Diseases, GI Diseases, CVS Disorders, Allergy and Others. Based on Distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Fast Melt Tablets Market

The growth of the Global Fast Melt Tablets market is significantly influenced by several factors. Chief among these is the increasing aging population, many of whom struggle with swallowing traditional pills. The heightened focus on product promotion aimed at improving consumer awareness and patient care is also contributing to market dynamics. As patients seek cost-effective solutions that enhance their quality of life, the demand for fast melt tablets continues to rise. Furthermore, the risks associated with choking or asphyxiation from conventional oral solid formulations underscore the necessity for alternatives. Technological advancements have enabled the development of fast melt tablets that dissolve swiftly, often within three minutes, thereby aligning with pharmacopoeia standards and further driving market growth.

Restraints in the Global Fast Melt Tablets Market

One significant constraint impacting the global fast melt tablets market is the difficulty associated with handling these products. Due to their porous and delicately formed structure, fast melt tablets lack robustness and are often created with minimal compression, rendering them fragile and prone to breakage. This vulnerability complicates storage, transportation, and dispensing processes, ultimately hindering market expansion. As a result, manufacturers face challenges in ensuring product integrity, which could lead to increased costs and limitations in distribution. Addressing these handling concerns is essential for overcoming barriers to growth within the fast melt tablets sector.

Market Trends of the Global Fast Melt Tablets Market

The Global Fast Melt Tablets market is experiencing robust growth, primarily fueled by the increasing demand from the geriatric population, who favor these formulations for their convenience and rapid action. Fast melt tablets eliminate first-pass metabolism issues associated with traditional oral medications, enhancing bioavailability and patient adherence. As this demographic seeks efficient self-administration options with fewer side effects, the trend towards fast-dissolving doses is gaining momentum. While technical challenges in formulation exist, ongoing research and development efforts are anticipated to address these hurdles, presenting significant opportunities for market expansion in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Fast Melt Tablets Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anti-Psychotics
• Anti-Epileptics
• CNS Stimulants
• Anxiolytics
• Anti-Parkinsonian Drugs
• Anti-Hypertensive
• NSAIDS
• Anti-Allergy Drugs
• Proton Pump Inhibitors
• Others

Global Fast Melt Tablets Market Size by Indication & CAGR (2025-2032)

• Market Overview
• CNS Diseases
• GI Diseases
• CVS Disorders
• Allergy
• Others

Global Fast Melt Tablets Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Global Fast Melt Tablets Market Size & CAGR (2025-2032)

• North America (Drug Class, Indication, Distribution channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Distribution channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Distribution channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Distribution channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Distribution channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kissei Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations